BioPharma Resources

Drug Trial Radar · NCT04198558

A Study of the Safety, Tolerability and Pharmacokinetics of MEDI0618 in Healthy Volunteers

A Randomised, Double-blind, Placebo-controlled Study of the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of MEDI0618 in Healthy Male and Female Volunteers

Last checked: Nov 19, 2026Latest source record: Oct 16, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

64

Actual

Start

Nov 29, 2019

Primary completion

Feb 23, 2022

Study completion Feb 23, 2022

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Dec 13, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Single (investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a randomised, placebo-controlled study of the safety and tolerability of single doses of MEDI0618 in healthy volunteer subjects.

Conditions

  • Chronic Pain

Interventions

  • MEDI0618Drug

    MEDI0618 A novel human immunoglobulin antibody

  • PlaceboDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]Time frame: Up to 85 days
  2. Incidence of Treatment-Emergent Serious Adverse EventsTime frame: Up to 85 days
  3. Vital SignsTime frame: Up to 85 days
  4. Vital SignsTime frame: Up to 85 days
  5. Body WeightTime frame: Up to 85 days
  6. HeightTime frame: Up to 85 days
  7. Clinical ChemistryTime frame: Up to 85 days
  8. HaematologyTime frame: Up to 85 days
  9. Thyroid FunctionTime frame: Up to 85 days
  10. Renal FunctionTime frame: Up to 85 days
  11. UrinalysisTime frame: Up to 85 days
  12. 12-Lead ElectrocardiogramTime frame: Up to 85 days
  13. Physical ExaminationTime frame: Up to 85 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Berlin, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.